Related Experiment Videos
ABH antigens and bone marrow transplantation
British Journal of Haematology
|January 1, 1980
Summary
ABH antigens do not significantly impact bone marrow transplant outcomes. Pre-transplant antibodies against these antigens can be managed, suggesting they are not critical for hematopoietic stem cell engraftment.
Area of Science:
- Immunogenetics
- Transplantation immunology
Background:
- Bone marrow transplantation (BMT) is a critical treatment for hematologic malignancies and aplastic anemia.
- The role of ABO, Lewis, and secretor status (collectively ABH antigens) in BMT outcomes remains debated.
- HLA-identical transplants minimize genetic disparities, allowing focus on other immunologic factors.
Observation:
- ABH antigen compatibility did not significantly influence graft rejection or graft-versus-host disease (GVHD) incidence in 104 HLA-identical BMT recipients.
- Fifteen recipients had pre-transplant anti-donor ABH antibodies.
- Successful antibody reduction via plasma exchange or marrow processing was achieved in most cases, enabling engraftment.
Findings:
- Pre-transplant ABH antibodies did not prevent engraftment, even when plasma exchange was unsuccessful.
- In vitro studies showed ABH antibodies did not inhibit hematopoietic progenitor cell growth (CFU-C, BFU-E).
- These results indicate ABH antigens are not clinically significant transplantation antigens.
Implications:
- ABH antigens may not be critical targets for pre-transplant antibody screening in HLA-identical BMT.
- The findings suggest ABH antigens are not operationally present on hematopoietic stem cells.
- Management strategies for anti-ABH antibodies can be refined, potentially simplifying BMT protocols.